NumerixS Investment Technologies Inc Purchases New Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

NumerixS Investment Technologies Inc purchased a new stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) during the first quarter, according to its most recent filing with the SEC. The firm purchased 15,000 shares of the biotechnology company’s stock, valued at approximately $190,000.

Several other large investors also recently made changes to their positions in IRWD. Gotham Asset Management LLC bought a new position in shares of Ironwood Pharmaceuticals during the 4th quarter worth about $135,000. Bank of Montreal Can lifted its holdings in shares of Ironwood Pharmaceuticals by 426.9% during the 4th quarter. Bank of Montreal Can now owns 16,846 shares of the biotechnology company’s stock worth $175,000 after acquiring an additional 13,649 shares during the period. Financial Counselors Inc. bought a new position in shares of Ironwood Pharmaceuticals during the 1st quarter worth about $204,000. Amalgamated Bank bought a new position in shares of Ironwood Pharmaceuticals during the 4th quarter worth about $211,000. Finally, Perennial Advisors LLC bought a new position in shares of Ironwood Pharmaceuticals during the 1st quarter worth about $243,000. Institutional investors and hedge funds own 99.22% of the company’s stock.

In other news, CFO Gina Consylman sold 4,055 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $10.53, for a total transaction of $42,699.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 5.90% of the stock is owned by insiders.

IRWD traded down $0.12 during midday trading on Wednesday, hitting $11.00. The company had a trading volume of 6,181 shares, compared to its average volume of 1,475,839. The stock has a market capitalization of $1.71 billion, a PE ratio of -11.62 and a beta of 1.78. Ironwood Pharmaceuticals, Inc. has a twelve month low of $9.07 and a twelve month high of $21.20.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.10). The business had revenue of $68.73 million for the quarter, compared to analysts’ expectations of $81.93 million. The company’s quarterly revenue was down .6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.25) EPS. On average, sell-side analysts expect that Ironwood Pharmaceuticals, Inc. will post -0.11 EPS for the current fiscal year.

A number of equities analysts have recently commented on the stock. BTIG Research set a $19.00 price objective on shares of Ironwood Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, February 14th. ValuEngine raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, February 13th. GMP Securities raised shares of Ironwood Pharmaceuticals from a “sell” rating to a “neutral” rating and lifted their price target for the company from $11.50 to $14.00 in a report on Monday, February 25th. BidaskClub downgraded shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, February 25th. Finally, Wood & Company began coverage on shares of Ironwood Pharmaceuticals in a report on Tuesday, February 26th. They set a “buy” rating for the company. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $15.15.

COPYRIGHT VIOLATION WARNING: This article was originally reported by WKRB News and is the sole property of of WKRB News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.wkrb13.com/2019/06/12/numerixs-investment-technologies-inc-purchases-new-holdings-in-ironwood-pharmaceuticals-inc-nasdaqirwd.html.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.

Featured Article: What are no-load funds?

Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD).

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.